Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
How do you approach the management of patients with moderate to high pre-test probabilty of GCA who are found to have negative findings on temporal artery biopsy?
Related Questions
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
Do you have safety concerns when prescribing GLP-1 medications in patients on corticosteroids or immunosuppressive therapy?
Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?
How do you decide when to use acid-suppressive medications for GI prophylaxis when patients are on prolonged corticosteroid therapy?
How do you approach treatment of livido vasculitis?
How would you approach failure of maintenance therapy (Azathioprine) for PR3 positive, c-ANCA positive, pulmonary–renal vasculitis previously induced with cyclophosphamide, with a history of anaphylaxis to rituximab?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?
Would you consider re-dosing rituximab in a patient with ANCA vasculitis (early glomerulonephritis, pulmonary nodules, sinus symptoms) who experiences a flare of the disease and return of CD19 cells 3 months after initial rituximab administration?
How do you approach hypogammaglobulinemia in a patient with sarcoidosis?
